Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report

Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histolog...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2024, pp.3155-23
Main Authors: Suzuki, Nobumi, Odawara, Nariaki, Fujisawa, Gota, Ishibashi, Rei, Hata, Masahiro, Oya, Yukiko, Tamada, Kenji, Hayashi, Takeshi, Abe, Sohei, Miyakawa, Yu, Hayakawa, Yoku, Shinozaki-Ushiku, Aya, Ushiku, Tetsuo, Boku, Narikazu, Fujishiro, Mitsuhiro
Format: Article
Language:English
Subjects:
gastric adenocarcinoma with enteroblastic differentiation
gastric cancer
HER2
trastuzumab deruxtecan
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.3155-23